Keywords: pozen, completes, ph, iii, program, mt, completed

Pozen completes Ph III program for MT 100

Article | 21 February 2001

Print This

Pozen has completed the final Phase III trial of its anti-migraine drugMT 100, a combination product of the approved drugs metoclopramide ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in